Videos

The senior director at the Banner Alzheimer's Institute talked about findings from the ancillary analyses of the US POINTER Study and the importance of strong recruitment efforts. [WATCH TIME: 5 minutes]

The head of search and evaluation at the Alzheimer's Drug Discovery Foundation discussed the evolving role of biomarkers for diagnosis and the progress of targeted therapies in Alzheimer disease. [WATCH TIME: 5 minutes]

In this segment, Wittlieb-Leber examines how vamorolone trials address long-standing questions about steroid exposure, cardiac risk, and meaningful cardiac endpoints in Duchenne.

The chief operating officer at Linus Health talked about how brief, digitally administered cognitive assessments enable scalable, earlier identification of cognitive impairment. [WATCH TIME: 4 minutes]

Pediatrics specialists discussed approaches to assessing depressive symptoms that may overlook key risk factors, highlighting the need for improved self-report measures, developmentally appropriate tools, and more precise symptom characterization. [WATCH TIME: 3 MINUTES]

The director at the National Center of Neurology and Psychiatry discussed how biomarker-driven diagnostics and antibody therapies targeting amyloid pathology may be reshaping Alzheimer disease management. [WATCH TIME: 4 minutes]

Pediatrics specialists discussed key methodological limitations of a recently published study, including variability across sites, reliance on caregiver-report measures, and the lack of developmentally appropriate tools for assessing depression in youth with intellectual disabilities. [WATCH TIME: 4 MINUTES]

Pediatric specialists reflected on the challenges and gaps in assessing depressive and anxiety symptoms among youth with epilepsy, emphasizing that patients with lower IQs are often excluded from research and clinical screening. [WATCH TIME: 3 MINUTES]

Neurology News Network for the week ending January 17, 2025. [WATCH TIME: 4 minutes]

Pediatric specialists reflected on the goal and findings of the study, describing the elevated prevalence of depressive symptoms among youth with epilepsy and highlighting temporal lobe epilepsy as a particularly high-risk subgroup. [WATCH TIME: 2 MINUTES]

The speakers review results from the TEMPO 1, 2, and 3 trials demonstrating that tavapadon improves motor symptoms as both monotherapy and adjunctive therapy in Parkinson’s disease. The drug may increase “on” time, reduce “off” time and dyskinesia, and potentially lessen the need for higher levodopa doses that contribute to motor fluctuations.

A panelist discusses how tavapadon’s D1/D5 receptor selectivity may offer potential benefits such as improved motor symptom control with a reduced risk of adverse effects commonly associated with traditional dopamine agonists.

In this segment, the physicians emphasize the importance of multidisciplinary care in managing the complex, lifelong needs of patients with NF1. One physician describes how comprehensive NF programs rely on coordinated input from neurology, ophthalmology, orthopedics, pulmonology, urology, endocrinology, dermatology, nephrology, neurosurgery, and psychosocial specialists to address the diverse medical and cognitive challenges associated with the condition. They highlight the essential role of neuropsychology, noting that many patients require ongoing assessment, educational support, and accommodations—services that are often harder to access in adulthood. The discussion then shifts to emerging treatments for plexiform neurofibromas. While MEK inhibitors remain the current standard, ongoing research is exploring combination therapies and novel agents with lower toxicity to reduce long-term treatment burdens. Finally, the physicians stress the need for proactive conversations about fertility, pregnancy safety, and “drug vacations” for young adults hoping to start families. They underscore the importance of genetic counseling and careful planning to balance treatment efficacy with reproductive goals.

At CTAD 2025, the director of Banner Alzheimer’s Institute discussed emerging epidemiologic and translational evidence suggesting that certain vaccines may confer protection against dementia. [WATCH TIME: 6 minutes]

The associate professor at The University of Tokyo talked about how lifestyle-focused multidomain interventions, including exercise, sleep, and nutrition, may improve cognitive function. [WATCH TIME: 4 minutes]

Genetic testing plays a crucial role in diagnosing Dravet syndrome early, guiding treatment plans, and improving patient outcomes.

Genetic testing plays a crucial role in diagnosing Dravet syndrome early, guiding treatment plans, and improving patient outcomes.

At MDS 2025, the professor of neurology at University de Tunis El Manar described the role of global collaboration in advancing the understanding, diagnosis, and management of Parkinson disease. [WATCH TIME: 6 minutes]

The research portfolio director at the Muscular Dystrophy Association spoke about ongoing advances in ALS research and how they may inform approaches to therapeutic development. [WATCH TIME: 5 minutes]

Joseph Sullivan, MD, discussed the importance of initiating transition-of-care conversations early and emphasizing psychosocial context when transferring adolescents with epilepsy to adult providers.

The clinical assistant professor at Feinberg School of Medicine outlined some of the major revisions proposed for the NMOSD diagnostic criteria presented at ECTRIMS 2025. [WATCH TIME: 8 minutes]

Neurology News Network for the week ending January 10, 2025. [WATCH TIME: 4 minutes]

In this segment, the physicians discuss how MEK inhibitor dosing differs between pediatric and adult patients with NF1-associated plexiform neurofibromas. One physician explains that children are typically dosed using weight-based or body surface area–based calculations, whereas adults receive standard fixed dosing. However, both physicians emphasize that individualized dosing is often necessary regardless of age. They describe how starting at a lower-than-recommended dose can reduce early side effects—an approach particularly valuable for adults who may discontinue treatment if initial tolerability is poor. The physicians note that some patients achieve meaningful clinical benefits, including pain reduction, even at these reduced doses, eliminating the need to escalate therapy. They highlight that dose adjustments should reflect patient goals, symptom severity, and overall tolerability, especially because many adults are treated primarily for pain relief rather than rapid tumor progression. Both clinicians acknowledge that while these modified approaches deviate from strict guidelines, they are widely practiced and often improve adherence and quality of life.

In this segment, the physicians explore the broad health maintenance needs and everyday challenges faced by adults with NF1 as they move further into their twenties and thirties. One physician notes that, beyond cancer surveillance, adults must manage cutaneous neurofibromas, increasing vascular risks, recurrent headaches, and hypertension—conditions that may signal vasculopathy or serious complications such as pheochromocytoma. The discussion highlights the importance of regular blood pressure monitoring and educating patients that even mild hypertension should not be ignored in the NF1 population. They also address treatment adherence, emphasizing that adults may discontinue MEK inhibitor therapy at the first sign of side effects, unlike pediatric patients whose parents manage their care. Clear expectations, proactive side-effect management, and structured “treatment contracts” help sustain adherence. Cognitive challenges—including ADHD, executive dysfunction, and intellectual disability—further complicate adult independence, employment, and insurance continuity. The physicians underscore the need for ongoing healthcare engagement, even when symptoms seem minimal, because NF1 remains a lifelong condition requiring continuous surveillance.

The speakers discuss the safety concerns associated with currently available dopamine agonists for Parkinson’s disease, including impulse control disorders, sleep attacks, and peripheral edema, which have contributed to decreased use over the past decade. They also highlight ongoing research into newer, third-generation dopamine agonists that may provide improved efficacy and fewer side effects.

The speakers review newer adjunctive therapies for managing motor fluctuations in Parkinson’s disease, including dopamine agonists, apomorphine infusion pumps, and the catechol-O-methyltransferase inhibitors, which helps prolong levodopa’s activity. They also emphasize the value of incorporating on-demand therapies alongside adjunctive medications to optimize symptom control and reduce “off” time.

At ECTRIMS 2025, the professor of biomedical engineering at the University of Bern discussed virtual reality technologies for multiple sclerosis rehabilitation. [WATCH TIME: 3 minutes]

Healthcare providers discuss the emotional challenges of addressing SUDEP with families of epilepsy patients, emphasizing the need for open communication and support.

Explore the patient journey of Dravet syndrome, including symptoms, diagnosis, and treatment options from expert perspectives and personal experiences.

The director of the EEG/Epilepsy Unit in the Department of Clinical Neurosciences at Lausanne University Hospital in Switzerland discussed post-anoxic seizure management at 2025 AES Annual Meeting. [WATCH TIME: 3 minutes]